NYXH VS GLSI Stock Comparison

Performance

NYXH
10/100

NYXH returned -15.83% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

GLSI
10/100

GLSI returned -0.90% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

NYXH
14/100

NYXH receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

GLSI
71/100

GLSI receives a 71 of 100 based on 14 indicators. 10 are bullish, 4 are bearish.

Earnings

NYXH
10/100

NYXH has missed earnings 5 times in the last 20 quarters.

GLSI
20/100

GLSI has missed earnings 4 times in the last 20 quarters.

Profit

NYXH
10/100

Out of the last 13 quarters, NYXH has had 0 profitable quarters and has increased their profits year over year on 0 of them.

GLSI
10/100

Out of the last 18 quarters, GLSI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

NYXH
45/100

NYXH has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

GLSI
42/100

GLSI has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

Sentiment

NYXH

"Sentiment" not found for NYXH

GLSI
71/100

GLSI had a bullish sentiment score of 71.12% across Twitter and StockTwits over the last 12 months. It had an average of 2.86 posts, 1.45 comments, and 6.05 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Nyxoah SA Ordinary Shares Summary

Nasdaq / NYXH

Healthcare

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Greenwich LifeSciences, Inc. Summary

Nasdaq / GLSI

Healthcare

Biotechnology

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Power up your portfolio